B Cell News and Research

RSS

New drug combination may treat two aggressive cancers

Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

13 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

UC Berkeley scientists offer treatment hope for patients with tinnitus

Neuroscientists at the University of California, Berkeley, are offering hope to the 10 percent of the population who suffer from tinnitus - a constant, often high-pitched ringing or buzzing in the ears that can be annoying and even maddening, and has no cure.

13 Sep 2011

Researchers identify new type of potential anticancer drug

Researchers at Emory University School of Medicine have identified a new type of potential anticancer drug. The compound, named FOBISIN, targets 14-3-3 proteins, important for the runaway growth of cancer cells.

13 Sep 2011

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

13 Sep 2011

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington’s patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington’s often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

12 Sep 2011

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

Reducing malaria incidence could also drastically reduce deaths from bacterial infections, study says

"Reducing the incidence of malaria could also drastically reduce the number of deaths from bacterial infections among children in Africa, a study" published last week in the Lancet found, according to SciDev.Net.

12 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Chromatin Inc. announced today that they have reached the first milestone in their research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company. This collaboration is focused on developing a novel combination of Chromatin's Mini-Chromosomes with Dow AgroSciences' EXZACT Precision Technology.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

Researchers identify glucokinase triggers beta cell regeneration in pancreas

Researchers at the Hebrew University of Jerusalem have identified the key signal that prompts production of insulin-producing beta cells in the pancreas -- a breakthrough discovery that may ultimately help researchers find ways to restore or increase beta cell function in people with type 1 diabetes.

12 Sep 2011

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

This year's Fernström Foundation Nordic Prize, with prize money of SEK 1 million, goes to Professor Anders Björklund from Lund University, Sweden. He is a neurology researcher focusing on neurodegenerative diseases, diseases in which the nerve cells die. Professor Björklund's research group is trying to develop customised stem cells to treat Parkinson's disease.

12 Sep 2011

IBN scientists harness ultrasmall peptides to repair spinal disc damage

New ultrasmall peptides that can be used as building blocks for a wide range of regenerative applications such as spinal disc replacement and cartilage repair have been developed by scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute. These peptides spontaneously assemble in water to form hydrogels, which resemble collagen, a major component of connective tissues found in cartilage, ligaments, tendons, bone and skin.

12 Sep 2011

Chronic pain gene discovered

Scientists have found the gene responsible for chronic pain. It said that this could lead to drugs for treating long-lasting back pain.

12 Sep 2011

Mayo Clinic develops genome-based immunization strategy against feline AIDS

Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The findings -- called fascinating and landmark by one reviewer -- appear in the current online issue of Nature Methods.

12 Sep 2011

B Cell News and Research

New drug combination may treat two aggressive cancers

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

UC Berkeley scientists offer treatment hope for patients with tinnitus

Researchers identify new type of potential anticancer drug

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

University of Adelaide research focuses on techniques to treat swallowing disorders

Reducing malaria incidence could also drastically reduce deaths from bacterial infections, study says

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Chromatin, Dow AgroSciences achieve first milestone in research collaboration

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Researchers identify glucokinase triggers beta cell regeneration in pancreas

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

IBN scientists harness ultrasmall peptides to repair spinal disc damage

Chronic pain gene discovered

Mayo Clinic develops genome-based immunization strategy against feline AIDS

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News